Ontology type: schema:ScholarlyArticle Open Access: True
2012-01-06
AUTHORSJosef Rüschoff, Wedad Hanna, Michael Bilous, Manfred Hofmann, Robert Y Osamura, Frédérique Penault-Llorca, Marc van de Vijver, Giuseppe Viale
ABSTRACTTrastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin is approved by the European Medicines Agency for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive (immunohistochemistry 3+ or immunohistochemistry 2+/fluorescence in situ hybridization-positive or immunohistochemistry 2+/silver in situ hybridization-positive) metastatic adenocarcinoma of the stomach or gastro–esophageal junction. Approvals are underway in other countries, with recent approvals granted in the United States and Japan. Experience and data from trastuzumab use in breast cancer have highlighted the importance of quality HER2 testing and scoring to ensure accurate identification of patients eligible for treatment. HER2 testing in gastric cancer differs from testing in breast cancer due to inherent differences in tumor biology; gastric cancer more frequently shows HER2 heterogeneity (focal staining) and incomplete membrane staining. Consequently, gastric cancer-specific HER2 testing protocols have been developed and standardized and it is imperative that these recommendations be adhered to. Given the predictive value of HER2 protein levels with response in the trastuzumab for GAstric cancer study (ToGA), immunohistochemistry should be the initial testing methodology and fluorescence in situ hybridization or silver in situ hybridization should be used to retest immunohistochemistry 2+ samples. Wherever possible, bright-field methodologies should be used as these are considered to be superior to fluorescent methodologies at identifying heterogeneous staining. Specific training is required before embarking on HER2 testing in gastric cancer, irrespective of the experience of HER2 testing in breast cancer. This paper provides the most up-to-date practical guidance on HER2 testing and scoring in patients with gastric and gastro–esophageal junction cancer, as agreed by a panel of expert pathologists with extensive experience of HER2 testing particularly reflecting the European Medicines Agency-approved indication. It is anticipated that these recommendations should ensure accurate and consistent HER2 testing, which will allow appropriate selection of patients eligible for treatment with trastuzumab. More... »
PAGES637-650
http://scigraph.springernature.com/pub.10.1038/modpathol.2011.198
DOIhttp://dx.doi.org/10.1038/modpathol.2011.198
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1027273989
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/22222640
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adenocarcinoma",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antibodies, Monoclonal, Humanized",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antineoplastic Agents",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Esophageal Neoplasms",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Esophagogastric Junction",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Immunohistochemistry",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "In Situ Hybridization",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Practice Guidelines as Topic",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Receptor, ErbB-2",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Silver Staining",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Stomach Neoplasms",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Trastuzumab",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Institute of Pathology Nordhessen, Kassel, Germany",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Targos Molecular Pathology GmbH, Kassel, Germany",
"Institute of Pathology Nordhessen, Kassel, Germany"
],
"type": "Organization"
},
"familyName": "R\u00fcschoff",
"givenName": "Josef",
"id": "sg:person.0655033461.67",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655033461.67"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Laboratory Medicine and Pathobiology, Anatomic Pathology, Sunnybrook Health Sciences Center, Faculty of Medicine, University of Toronto, Toronto, Canada",
"id": "http://www.grid.ac/institutes/grid.413104.3",
"name": [
"Department of Laboratory Medicine and Pathobiology, Anatomic Pathology, Sunnybrook Health Sciences Center, Faculty of Medicine, University of Toronto, Toronto, Canada"
],
"type": "Organization"
},
"familyName": "Hanna",
"givenName": "Wedad",
"id": "sg:person.0755325725.02",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755325725.02"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Healthscope Pathology, Norwest Private Hospital, Faculty of Medicine University of Sydney, Sydney, Australia",
"id": "http://www.grid.ac/institutes/grid.1013.3",
"name": [
"Healthscope Pathology, Norwest Private Hospital, Faculty of Medicine University of Sydney, Sydney, Australia"
],
"type": "Organization"
},
"familyName": "Bilous",
"givenName": "Michael",
"id": "sg:person.01047412262.17",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047412262.17"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Institute of Pathology Nordhessen, Kassel, Germany",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Institute of Pathology Nordhessen, Kassel, Germany"
],
"type": "Organization"
},
"familyName": "Hofmann",
"givenName": "Manfred",
"id": "sg:person.01346453747.06",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346453747.06"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "International University of Health and Welfare (IUHW), Center for Diagnostic Pathology, IUHW Mita Hospital, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/grid.415958.4",
"name": [
"International University of Health and Welfare (IUHW), Center for Diagnostic Pathology, IUHW Mita Hospital, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Osamura",
"givenName": "Robert Y",
"id": "sg:person.01356461514.40",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356461514.40"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Pathology, Centre Jean Perrin and University of Auvergne, Clermont-Ferrand, France",
"id": "http://www.grid.ac/institutes/grid.494717.8",
"name": [
"Department of Pathology, Centre Jean Perrin and University of Auvergne, Clermont-Ferrand, France"
],
"type": "Organization"
},
"familyName": "Penault-Llorca",
"givenName": "Fr\u00e9d\u00e9rique",
"id": "sg:person.0643603315.57",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643603315.57"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Pathology, The Academic Medical Center (AMC), The University of Amsterdam, Amsterdam, The Netherlands",
"id": "http://www.grid.ac/institutes/grid.7177.6",
"name": [
"Department of Pathology, The Academic Medical Center (AMC), The University of Amsterdam, Amsterdam, The Netherlands"
],
"type": "Organization"
},
"familyName": "van de Vijver",
"givenName": "Marc",
"id": "sg:person.01367247364.80",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367247364.80"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Pathology and Laboratory Medicine, University of Milan and European Institute of Oncology, Milan, Italy",
"id": "http://www.grid.ac/institutes/grid.15667.33",
"name": [
"Department of Pathology and Laboratory Medicine, University of Milan and European Institute of Oncology, Milan, Italy"
],
"type": "Organization"
},
"familyName": "Viale",
"givenName": "Giuseppe",
"id": "sg:person.012777104037.00",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012777104037.00"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/s00292-010-1278-1",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1044174834",
"https://doi.org/10.1007/s00292-010-1278-1"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/modpathol.3800774",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1035152373",
"https://doi.org/10.1038/modpathol.3800774"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10620-005-9057-1",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1006218639",
"https://doi.org/10.1007/s10620-005-9057-1"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1097/01.mp.0000052102.90815.82",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1043809974",
"https://doi.org/10.1097/01.mp.0000052102.90815.82"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10190-009-0037-8",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1038032671",
"https://doi.org/10.1007/s10190-009-0037-8"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00428-010-0952-2",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1008262506",
"https://doi.org/10.1007/s00428-010-0952-2"
],
"type": "CreativeWork"
}
],
"datePublished": "2012-01-06",
"datePublishedReg": "2012-01-06",
"description": "Trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin is approved by the European Medicines Agency for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive (immunohistochemistry 3+ or immunohistochemistry 2+/fluorescence in situ hybridization-positive or immunohistochemistry 2+/silver in situ hybridization-positive) metastatic adenocarcinoma of the stomach or gastro\u2013esophageal junction. Approvals are underway in other countries, with recent approvals granted in the United States and Japan. Experience and data from trastuzumab use in breast cancer have highlighted the importance of quality HER2 testing and scoring to ensure accurate identification of patients eligible for treatment. HER2 testing in gastric cancer differs from testing in breast cancer due to inherent differences in tumor biology; gastric cancer more frequently shows HER2 heterogeneity (focal staining) and incomplete membrane staining. Consequently, gastric cancer-specific HER2 testing protocols have been developed and standardized and it is imperative that these recommendations be adhered to. Given the predictive value of HER2 protein levels with response in the trastuzumab for GAstric cancer study (ToGA), immunohistochemistry should be the initial testing methodology and fluorescence in situ hybridization or silver in situ hybridization should be used to retest immunohistochemistry 2+ samples. Wherever possible, bright-field methodologies should be used as these are considered to be superior to fluorescent methodologies at identifying heterogeneous staining. Specific training is required before embarking on HER2 testing in gastric cancer, irrespective of the experience of HER2 testing in breast cancer. This paper provides the most up-to-date practical guidance on HER2 testing and scoring in patients with gastric and gastro\u2013esophageal junction cancer, as agreed by a panel of expert pathologists with extensive experience of HER2 testing particularly reflecting the European Medicines Agency-approved indication. It is anticipated that these recommendations should ensure accurate and consistent HER2 testing, which will allow appropriate selection of patients eligible for treatment with trastuzumab.",
"genre": "article",
"id": "sg:pub.10.1038/modpathol.2011.198",
"inLanguage": "en",
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1098208",
"issn": [
"0893-3952",
"1530-0285"
],
"name": "Modern Pathology",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "5",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "25"
}
],
"keywords": [
"HER2 testing",
"European Medicines Agency",
"breast cancer",
"gastric cancer",
"Medicines Agency",
"gastro-esophageal junction cancer",
"human epidermal growth factor receptor 2",
"epidermal growth factor receptor 2",
"growth factor receptor 2",
"gastro-esophageal junction",
"treatment of patients",
"HER2 protein levels",
"Gastric Cancer Study",
"gastric cancer differs",
"factor receptor 2",
"incomplete membrane staining",
"trastuzumab use",
"metastatic adenocarcinoma",
"junction cancer",
"situ hybridization",
"immunohistochemistry 2",
"cancer differs",
"receptor 2",
"HER2 heterogeneity",
"predictive value",
"patients",
"recent approval",
"tumor biology",
"cancer",
"HER2",
"trastuzumab",
"heterogeneous staining",
"cancer studies",
"membrane staining",
"protein levels",
"expert pathologists",
"treatment",
"fluorescent methodologies",
"specific training",
"staining",
"testing protocol",
"approval",
"extensive experience",
"capecitabine",
"adenocarcinoma",
"gastric",
"testing",
"immunohistochemistry",
"stomach",
"cisplatin",
"pathologists",
"accurate identification",
"United States",
"recommendations",
"experience",
"inherent differences",
"indications",
"appropriate selection",
"scoring",
"hybridization",
"response",
"practical approach",
"practical guidance",
"levels",
"differences",
"study",
"protocol",
"training",
"panel",
"heterogeneity",
"guidance",
"junction",
"use",
"combination",
"differs",
"identification",
"samples",
"data",
"biology",
"countries",
"Japan",
"importance",
"agencies",
"values",
"testing methodology",
"fluorescence",
"selection",
"approach",
"state",
"methodology",
"silver",
"paper"
],
"name": "HER2 testing in gastric cancer: a practical approach",
"pagination": "637-650",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1027273989"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1038/modpathol.2011.198"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"22222640"
]
}
],
"sameAs": [
"https://doi.org/10.1038/modpathol.2011.198",
"https://app.dimensions.ai/details/publication/pub.1027273989"
],
"sdDataset": "articles",
"sdDatePublished": "2022-05-20T07:28",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_567.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1038/modpathol.2011.198"
}
]
Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/modpathol.2011.198'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/modpathol.2011.198'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/modpathol.2011.198'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/modpathol.2011.198'
This table displays all metadata directly associated to this object as RDF triples.
298 TRIPLES
22 PREDICATES
137 URIs
123 LITERALS
20 BLANK NODES
Subject | Predicate | Object | |
---|---|---|---|
1 | sg:pub.10.1038/modpathol.2011.198 | schema:about | N0fbe641c81914dcaaac66f7b5ac927a2 |
2 | ″ | ″ | N32b070343b524fedb59183f6c50bbdbf |
3 | ″ | ″ | N374aeedecbe34676995e42628cfc6853 |
4 | ″ | ″ | N4d0d1eb0bcdf43e282991dd8f2a859e5 |
5 | ″ | ″ | N6191385b4b25453ea590095a725379bf |
6 | ″ | ″ | N7a357ce937b64c44a2d388e873d67938 |
7 | ″ | ″ | N8e1845aaf0af49ecae3afd88d3fa90f9 |
8 | ″ | ″ | N8e80479a12204afd852b92d98253d183 |
9 | ″ | ″ | Nb3abb77d2cfb4584822c52d5948f7b6f |
10 | ″ | ″ | Nc549791578e54a789f6e7a30305ca425 |
11 | ″ | ″ | Ncd716740dcdc486aac8e3d3afaeaeb4e |
12 | ″ | ″ | Nd2f636a6f8194b8681f33bdd6309bf01 |
13 | ″ | ″ | Nd5e4ceb19a6e4b4a8e7254d303c7793b |
14 | ″ | ″ | anzsrc-for:11 |
15 | ″ | ″ | anzsrc-for:1112 |
16 | ″ | schema:author | N3ec4f6d861fe45c0a9c08dec5d231a12 |
17 | ″ | schema:citation | sg:pub.10.1007/s00292-010-1278-1 |
18 | ″ | ″ | sg:pub.10.1007/s00428-010-0952-2 |
19 | ″ | ″ | sg:pub.10.1007/s10190-009-0037-8 |
20 | ″ | ″ | sg:pub.10.1007/s10620-005-9057-1 |
21 | ″ | ″ | sg:pub.10.1038/modpathol.3800774 |
22 | ″ | ″ | sg:pub.10.1097/01.mp.0000052102.90815.82 |
23 | ″ | schema:datePublished | 2012-01-06 |
24 | ″ | schema:datePublishedReg | 2012-01-06 |
25 | ″ | schema:description | Trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin is approved by the European Medicines Agency for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive (immunohistochemistry 3+ or immunohistochemistry 2+/fluorescence in situ hybridization-positive or immunohistochemistry 2+/silver in situ hybridization-positive) metastatic adenocarcinoma of the stomach or gastro–esophageal junction. Approvals are underway in other countries, with recent approvals granted in the United States and Japan. Experience and data from trastuzumab use in breast cancer have highlighted the importance of quality HER2 testing and scoring to ensure accurate identification of patients eligible for treatment. HER2 testing in gastric cancer differs from testing in breast cancer due to inherent differences in tumor biology; gastric cancer more frequently shows HER2 heterogeneity (focal staining) and incomplete membrane staining. Consequently, gastric cancer-specific HER2 testing protocols have been developed and standardized and it is imperative that these recommendations be adhered to. Given the predictive value of HER2 protein levels with response in the trastuzumab for GAstric cancer study (ToGA), immunohistochemistry should be the initial testing methodology and fluorescence in situ hybridization or silver in situ hybridization should be used to retest immunohistochemistry 2+ samples. Wherever possible, bright-field methodologies should be used as these are considered to be superior to fluorescent methodologies at identifying heterogeneous staining. Specific training is required before embarking on HER2 testing in gastric cancer, irrespective of the experience of HER2 testing in breast cancer. This paper provides the most up-to-date practical guidance on HER2 testing and scoring in patients with gastric and gastro–esophageal junction cancer, as agreed by a panel of expert pathologists with extensive experience of HER2 testing particularly reflecting the European Medicines Agency-approved indication. It is anticipated that these recommendations should ensure accurate and consistent HER2 testing, which will allow appropriate selection of patients eligible for treatment with trastuzumab. |
26 | ″ | schema:genre | article |
27 | ″ | schema:inLanguage | en |
28 | ″ | schema:isAccessibleForFree | true |
29 | ″ | schema:isPartOf | Na904cd2152f14c9da7e651ac225a4c1c |
30 | ″ | ″ | Nb34f86456398450ea96b40f9569d89da |
31 | ″ | ″ | sg:journal.1098208 |
32 | ″ | schema:keywords | European Medicines Agency |
33 | ″ | ″ | Gastric Cancer Study |
34 | ″ | ″ | HER2 |
35 | ″ | ″ | HER2 heterogeneity |
36 | ″ | ″ | HER2 protein levels |
37 | ″ | ″ | HER2 testing |
38 | ″ | ″ | Japan |
39 | ″ | ″ | Medicines Agency |
40 | ″ | ″ | United States |
41 | ″ | ″ | accurate identification |
42 | ″ | ″ | adenocarcinoma |
43 | ″ | ″ | agencies |
44 | ″ | ″ | approach |
45 | ″ | ″ | appropriate selection |
46 | ″ | ″ | approval |
47 | ″ | ″ | biology |
48 | ″ | ″ | breast cancer |
49 | ″ | ″ | cancer |
50 | ″ | ″ | cancer differs |
51 | ″ | ″ | cancer studies |
52 | ″ | ″ | capecitabine |
53 | ″ | ″ | cisplatin |
54 | ″ | ″ | combination |
55 | ″ | ″ | countries |
56 | ″ | ″ | data |
57 | ″ | ″ | differences |
58 | ″ | ″ | differs |
59 | ″ | ″ | epidermal growth factor receptor 2 |
60 | ″ | ″ | experience |
61 | ″ | ″ | expert pathologists |
62 | ″ | ″ | extensive experience |
63 | ″ | ″ | factor receptor 2 |
64 | ″ | ″ | fluorescence |
65 | ″ | ″ | fluorescent methodologies |
66 | ″ | ″ | gastric |
67 | ″ | ″ | gastric cancer |
68 | ″ | ″ | gastric cancer differs |
69 | ″ | ″ | gastro-esophageal junction |
70 | ″ | ″ | gastro-esophageal junction cancer |
71 | ″ | ″ | growth factor receptor 2 |
72 | ″ | ″ | guidance |
73 | ″ | ″ | heterogeneity |
74 | ″ | ″ | heterogeneous staining |
75 | ″ | ″ | human epidermal growth factor receptor 2 |
76 | ″ | ″ | hybridization |
77 | ″ | ″ | identification |
78 | ″ | ″ | immunohistochemistry |
79 | ″ | ″ | immunohistochemistry 2 |
80 | ″ | ″ | importance |
81 | ″ | ″ | incomplete membrane staining |
82 | ″ | ″ | indications |
83 | ″ | ″ | inherent differences |
84 | ″ | ″ | junction |
85 | ″ | ″ | junction cancer |
86 | ″ | ″ | levels |
87 | ″ | ″ | membrane staining |
88 | ″ | ″ | metastatic adenocarcinoma |
89 | ″ | ″ | methodology |
90 | ″ | ″ | panel |
91 | ″ | ″ | paper |
92 | ″ | ″ | pathologists |
93 | ″ | ″ | patients |
94 | ″ | ″ | practical approach |
95 | ″ | ″ | practical guidance |
96 | ″ | ″ | predictive value |
97 | ″ | ″ | protein levels |
98 | ″ | ″ | protocol |
99 | ″ | ″ | recent approval |
100 | ″ | ″ | receptor 2 |
101 | ″ | ″ | recommendations |
102 | ″ | ″ | response |
103 | ″ | ″ | samples |
104 | ″ | ″ | scoring |
105 | ″ | ″ | selection |
106 | ″ | ″ | silver |
107 | ″ | ″ | situ hybridization |
108 | ″ | ″ | specific training |
109 | ″ | ″ | staining |
110 | ″ | ″ | state |
111 | ″ | ″ | stomach |
112 | ″ | ″ | study |
113 | ″ | ″ | testing |
114 | ″ | ″ | testing methodology |
115 | ″ | ″ | testing protocol |
116 | ″ | ″ | training |
117 | ″ | ″ | trastuzumab |
118 | ″ | ″ | trastuzumab use |
119 | ″ | ″ | treatment |
120 | ″ | ″ | treatment of patients |
121 | ″ | ″ | tumor biology |
122 | ″ | ″ | use |
123 | ″ | ″ | values |
124 | ″ | schema:name | HER2 testing in gastric cancer: a practical approach |
125 | ″ | schema:pagination | 637-650 |
126 | ″ | schema:productId | N37684f6271604111a024fed8f02717eb |
127 | ″ | ″ | N985be9a36286489095b6fbf16298053c |
128 | ″ | ″ | Nbe3e24bb7aac4cf29d7b8603e067504a |
129 | ″ | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1027273989 |
130 | ″ | ″ | https://doi.org/10.1038/modpathol.2011.198 |
131 | ″ | schema:sdDatePublished | 2022-05-20T07:28 |
132 | ″ | schema:sdLicense | https://scigraph.springernature.com/explorer/license/ |
133 | ″ | schema:sdPublisher | N64402abfdb8442fc9b5b6aa9aaa0dbdc |
134 | ″ | schema:url | https://doi.org/10.1038/modpathol.2011.198 |
135 | ″ | sgo:license | sg:explorer/license/ |
136 | ″ | sgo:sdDataset | articles |
137 | ″ | rdf:type | schema:ScholarlyArticle |
138 | N04dc2118ce0648c8835b26a18769d3af | rdf:first | sg:person.01367247364.80 |
139 | ″ | rdf:rest | N733c871ddb824f69afeafa3da5603d80 |
140 | N0fbe641c81914dcaaac66f7b5ac927a2 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
141 | ″ | schema:name | Silver Staining |
142 | ″ | rdf:type | schema:DefinedTerm |
143 | N28f2b2abb83a4e5089761e44a10133c9 | rdf:first | sg:person.0643603315.57 |
144 | ″ | rdf:rest | N04dc2118ce0648c8835b26a18769d3af |
145 | N32b070343b524fedb59183f6c50bbdbf | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
146 | ″ | schema:name | Practice Guidelines as Topic |
147 | ″ | rdf:type | schema:DefinedTerm |
148 | N374aeedecbe34676995e42628cfc6853 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
149 | ″ | schema:name | Stomach Neoplasms |
150 | ″ | rdf:type | schema:DefinedTerm |
151 | N37684f6271604111a024fed8f02717eb | schema:name | doi |
152 | ″ | schema:value | 10.1038/modpathol.2011.198 |
153 | ″ | rdf:type | schema:PropertyValue |
154 | N3ec4f6d861fe45c0a9c08dec5d231a12 | rdf:first | sg:person.0655033461.67 |
155 | ″ | rdf:rest | Na578c77cfc9f458c8c4268ab9ca5e5c6 |
156 | N4d0d1eb0bcdf43e282991dd8f2a859e5 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
157 | ″ | schema:name | Immunohistochemistry |
158 | ″ | rdf:type | schema:DefinedTerm |
159 | N6191385b4b25453ea590095a725379bf | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
160 | ″ | schema:name | Trastuzumab |
161 | ″ | rdf:type | schema:DefinedTerm |
162 | N64402abfdb8442fc9b5b6aa9aaa0dbdc | schema:name | Springer Nature - SN SciGraph project |
163 | ″ | rdf:type | schema:Organization |
164 | N733c871ddb824f69afeafa3da5603d80 | rdf:first | sg:person.012777104037.00 |
165 | ″ | rdf:rest | rdf:nil |
166 | N7a357ce937b64c44a2d388e873d67938 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
167 | ″ | schema:name | Humans |
168 | ″ | rdf:type | schema:DefinedTerm |
169 | N8e1845aaf0af49ecae3afd88d3fa90f9 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
170 | ″ | schema:name | Receptor, ErbB-2 |
171 | ″ | rdf:type | schema:DefinedTerm |
172 | N8e80479a12204afd852b92d98253d183 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
173 | ″ | schema:name | In Situ Hybridization |
174 | ″ | rdf:type | schema:DefinedTerm |
175 | N985be9a36286489095b6fbf16298053c | schema:name | pubmed_id |
176 | ″ | schema:value | 22222640 |
177 | ″ | rdf:type | schema:PropertyValue |
178 | Na578c77cfc9f458c8c4268ab9ca5e5c6 | rdf:first | sg:person.0755325725.02 |
179 | ″ | rdf:rest | Naab618078edb49febc53528c3ef833a2 |
180 | Na904cd2152f14c9da7e651ac225a4c1c | schema:issueNumber | 5 |
181 | ″ | rdf:type | schema:PublicationIssue |
182 | Naab618078edb49febc53528c3ef833a2 | rdf:first | sg:person.01047412262.17 |
183 | ″ | rdf:rest | Nd4190a44e70443a09a3b0185e1154cc3 |
184 | Nb34f86456398450ea96b40f9569d89da | schema:volumeNumber | 25 |
185 | ″ | rdf:type | schema:PublicationVolume |
186 | Nb3abb77d2cfb4584822c52d5948f7b6f | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
187 | ″ | schema:name | Esophagogastric Junction |
188 | ″ | rdf:type | schema:DefinedTerm |
189 | Nbe3e24bb7aac4cf29d7b8603e067504a | schema:name | dimensions_id |
190 | ″ | schema:value | pub.1027273989 |
191 | ″ | rdf:type | schema:PropertyValue |
192 | Nc549791578e54a789f6e7a30305ca425 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
193 | ″ | schema:name | Antibodies, Monoclonal, Humanized |
194 | ″ | rdf:type | schema:DefinedTerm |
195 | Ncd716740dcdc486aac8e3d3afaeaeb4e | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
196 | ″ | schema:name | Antineoplastic Agents |
197 | ″ | rdf:type | schema:DefinedTerm |
198 | Nd2f636a6f8194b8681f33bdd6309bf01 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
199 | ″ | schema:name | Esophageal Neoplasms |
200 | ″ | rdf:type | schema:DefinedTerm |
201 | Nd4190a44e70443a09a3b0185e1154cc3 | rdf:first | sg:person.01346453747.06 |
202 | ″ | rdf:rest | Ne529620631d6409b8a921c1bf71b7b45 |
203 | Nd5e4ceb19a6e4b4a8e7254d303c7793b | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
204 | ″ | schema:name | Adenocarcinoma |
205 | ″ | rdf:type | schema:DefinedTerm |
206 | Ne529620631d6409b8a921c1bf71b7b45 | rdf:first | sg:person.01356461514.40 |
207 | ″ | rdf:rest | N28f2b2abb83a4e5089761e44a10133c9 |
208 | anzsrc-for:11 | schema:inDefinedTermSet | anzsrc-for: |
209 | ″ | schema:name | Medical and Health Sciences |
210 | ″ | rdf:type | schema:DefinedTerm |
211 | anzsrc-for:1112 | schema:inDefinedTermSet | anzsrc-for: |
212 | ″ | schema:name | Oncology and Carcinogenesis |
213 | ″ | rdf:type | schema:DefinedTerm |
214 | sg:journal.1098208 | schema:issn | 0893-3952 |
215 | ″ | ″ | 1530-0285 |
216 | ″ | schema:name | Modern Pathology |
217 | ″ | schema:publisher | Springer Nature |
218 | ″ | rdf:type | schema:Periodical |
219 | sg:person.01047412262.17 | schema:affiliation | grid-institutes:grid.1013.3 |
220 | ″ | schema:familyName | Bilous |
221 | ″ | schema:givenName | Michael |
222 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047412262.17 |
223 | ″ | rdf:type | schema:Person |
224 | sg:person.012777104037.00 | schema:affiliation | grid-institutes:grid.15667.33 |
225 | ″ | schema:familyName | Viale |
226 | ″ | schema:givenName | Giuseppe |
227 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012777104037.00 |
228 | ″ | rdf:type | schema:Person |
229 | sg:person.01346453747.06 | schema:affiliation | grid-institutes:None |
230 | ″ | schema:familyName | Hofmann |
231 | ″ | schema:givenName | Manfred |
232 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346453747.06 |
233 | ″ | rdf:type | schema:Person |
234 | sg:person.01356461514.40 | schema:affiliation | grid-institutes:grid.415958.4 |
235 | ″ | schema:familyName | Osamura |
236 | ″ | schema:givenName | Robert Y |
237 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356461514.40 |
238 | ″ | rdf:type | schema:Person |
239 | sg:person.01367247364.80 | schema:affiliation | grid-institutes:grid.7177.6 |
240 | ″ | schema:familyName | van de Vijver |
241 | ″ | schema:givenName | Marc |
242 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367247364.80 |
243 | ″ | rdf:type | schema:Person |
244 | sg:person.0643603315.57 | schema:affiliation | grid-institutes:grid.494717.8 |
245 | ″ | schema:familyName | Penault-Llorca |
246 | ″ | schema:givenName | Frédérique |
247 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643603315.57 |
248 | ″ | rdf:type | schema:Person |
249 | sg:person.0655033461.67 | schema:affiliation | grid-institutes:None |
250 | ″ | schema:familyName | Rüschoff |
251 | ″ | schema:givenName | Josef |
252 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655033461.67 |
253 | ″ | rdf:type | schema:Person |
254 | sg:person.0755325725.02 | schema:affiliation | grid-institutes:grid.413104.3 |
255 | ″ | schema:familyName | Hanna |
256 | ″ | schema:givenName | Wedad |
257 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755325725.02 |
258 | ″ | rdf:type | schema:Person |
259 | sg:pub.10.1007/s00292-010-1278-1 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1044174834 |
260 | ″ | ″ | https://doi.org/10.1007/s00292-010-1278-1 |
261 | ″ | rdf:type | schema:CreativeWork |
262 | sg:pub.10.1007/s00428-010-0952-2 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1008262506 |
263 | ″ | ″ | https://doi.org/10.1007/s00428-010-0952-2 |
264 | ″ | rdf:type | schema:CreativeWork |
265 | sg:pub.10.1007/s10190-009-0037-8 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1038032671 |
266 | ″ | ″ | https://doi.org/10.1007/s10190-009-0037-8 |
267 | ″ | rdf:type | schema:CreativeWork |
268 | sg:pub.10.1007/s10620-005-9057-1 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1006218639 |
269 | ″ | ″ | https://doi.org/10.1007/s10620-005-9057-1 |
270 | ″ | rdf:type | schema:CreativeWork |
271 | sg:pub.10.1038/modpathol.3800774 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1035152373 |
272 | ″ | ″ | https://doi.org/10.1038/modpathol.3800774 |
273 | ″ | rdf:type | schema:CreativeWork |
274 | sg:pub.10.1097/01.mp.0000052102.90815.82 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1043809974 |
275 | ″ | ″ | https://doi.org/10.1097/01.mp.0000052102.90815.82 |
276 | ″ | rdf:type | schema:CreativeWork |
277 | grid-institutes:None | schema:alternateName | Institute of Pathology Nordhessen, Kassel, Germany |
278 | ″ | schema:name | Institute of Pathology Nordhessen, Kassel, Germany |
279 | ″ | ″ | Targos Molecular Pathology GmbH, Kassel, Germany |
280 | ″ | rdf:type | schema:Organization |
281 | grid-institutes:grid.1013.3 | schema:alternateName | Healthscope Pathology, Norwest Private Hospital, Faculty of Medicine University of Sydney, Sydney, Australia |
282 | ″ | schema:name | Healthscope Pathology, Norwest Private Hospital, Faculty of Medicine University of Sydney, Sydney, Australia |
283 | ″ | rdf:type | schema:Organization |
284 | grid-institutes:grid.15667.33 | schema:alternateName | Department of Pathology and Laboratory Medicine, University of Milan and European Institute of Oncology, Milan, Italy |
285 | ″ | schema:name | Department of Pathology and Laboratory Medicine, University of Milan and European Institute of Oncology, Milan, Italy |
286 | ″ | rdf:type | schema:Organization |
287 | grid-institutes:grid.413104.3 | schema:alternateName | Department of Laboratory Medicine and Pathobiology, Anatomic Pathology, Sunnybrook Health Sciences Center, Faculty of Medicine, University of Toronto, Toronto, Canada |
288 | ″ | schema:name | Department of Laboratory Medicine and Pathobiology, Anatomic Pathology, Sunnybrook Health Sciences Center, Faculty of Medicine, University of Toronto, Toronto, Canada |
289 | ″ | rdf:type | schema:Organization |
290 | grid-institutes:grid.415958.4 | schema:alternateName | International University of Health and Welfare (IUHW), Center for Diagnostic Pathology, IUHW Mita Hospital, Tokyo, Japan |
291 | ″ | schema:name | International University of Health and Welfare (IUHW), Center for Diagnostic Pathology, IUHW Mita Hospital, Tokyo, Japan |
292 | ″ | rdf:type | schema:Organization |
293 | grid-institutes:grid.494717.8 | schema:alternateName | Department of Pathology, Centre Jean Perrin and University of Auvergne, Clermont-Ferrand, France |
294 | ″ | schema:name | Department of Pathology, Centre Jean Perrin and University of Auvergne, Clermont-Ferrand, France |
295 | ″ | rdf:type | schema:Organization |
296 | grid-institutes:grid.7177.6 | schema:alternateName | Department of Pathology, The Academic Medical Center (AMC), The University of Amsterdam, Amsterdam, The Netherlands |
297 | ″ | schema:name | Department of Pathology, The Academic Medical Center (AMC), The University of Amsterdam, Amsterdam, The Netherlands |
298 | ″ | rdf:type | schema:Organization |